Inxmed (shanghai) Co., Ltd.
Clinical trials sponsored by Inxmed (shanghai) Co., Ltd., explained in plain language.
-
Cancer combo trial pulled before it even started
Disease control TerminatedThis study was designed to test a new oral drug called IN10018 combined with chemotherapy (nab-paclitaxel) and an immunotherapy (tislelizumab) in people with advanced solid tumors, specifically non-small cell lung cancer, that had stopped responding to prior treatments. The goal …
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 12:08 UTC
-
New drug duo targets hard-to-treat cancers with KRAS mutation
Disease control OngoingThis study tests two experimental drugs, D-1553 and IN10018, together in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 140 adults…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC